Rolipram does not normalize very long‐chain fatty acid levels in adrenoleukodystrophy protein‐deficient fibroblasts and mice

In its severe form, X‐linked adrenoleukodystrophy (X‐ALD) is a lethal neurodegenerative disorder with inflammatory demyelination, in which defective peroxisomal β‐oxidation causes accumulation of very long‐chain fatty acids (VLCFA) in tissues and plasma, in particular in the nervous system and adrenal glands. Recently, several drugs have been reported to reduce VLCFA in cultured human fibroblasts of X‐ALD patients, and therefore to be potential candidates for novel therapeutic treatments in X‐ALD. Among the most promising of these substances is the antidepressant rolipram, because of favourable adverse event profile in clinical studies and its additionally reported anti‐inflammatory action. To further elucidate the effects of rolipram on peroxisomal β‐oxidation and VLCFA accumulation, we administered rolipram orally in the diet to ALD protein‐deficient mice and ALD protein‐deficient cultured human and mouse fibroblasts and assayed the accumulation of VLCFA. In contrast to the previously reported reduction of VLCFA, our data did not demonstrate a decrease in VLCFA content either in vivo or in vitro . NMR spectroscopic analysis verified the structural integrity and purity of the rolipram used here, thus excluding inauthenticity as a reason for the discrepancy. We therefore suggest that rolipram should be excluded from the current list of potential therapeutic agents for X‐ALD.